1. Scrip
  2. >>Business
  3. >>Earnings

GSK Can Finally Claim A Turnaround Thanks To Arexvy’s Blockbuster Launch

 
• By Andrew McConaghie

GSK’s RSV vaccine Arexvy is a clear early winner against Pfizer’s rival, prompting analysts to finally turn optimistic about the company’s long-term prospects.

GSK

After years in the doldrums, GSK finally looks on course to complete a turnaround in its business.

The product which sealed this reversal of fortune is new respiratory syncytial virus vaccine Arexvy – it has reached $1bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial